News

Lysogene has completed the enrollment in its “Sanfilippo A Multi-national Observational Study” (SAMOS). Sanfilippo A is also known as Mucopolysaccharidosis Type IIIA (MPS IIIA).…
Read More...

Lysogene and Brammer Bio has entered into manufacturing agreement. Brammer Bio will produce an AAVrh10-based gene therapy, LYS-GM101 for clinical testing of the therapeutic candidate in…
Read More...

US Patent and Trade Office (USPTO) has issued Notice of Allowance to Neurana Pharmaceuticals for two new tolperisone patents, including a second Composition of Matter patent for a novel…
Read More...

US FDA has granted Orphan Drug Designation (ODD) for Abeona’s EB-101 gene therapy program for patients with dystrophic epidermolysis bullosa (DEB), including recessive dystrophic…
Read More...

Optibrium has entered into a collaboration with Imperial College London for developing new treatments for neglected diseases as part of a collaborative project with DNDi (Drugs for…
Read More...

The US FDA Oncologic Drugs Advisory Committee (ODAC) recommended the approval of the Pizer’s proposed epoetin alfa biosimilar across all indications. The Committee’s favorable…
Read More...

X4 Pharmaceuticals announced dosing of the first patient in the Phase 2 portion of the ongoing Phase 1/2 study evaluating X4P-001, the CXCR4 inhibitor, in combination with Inlyta…
Read More...

The US FDA accepted Bristol-Myers Squibb supplemental BLA to extend the use of Opdivo (nivolumab) to patients with hepatocellular carcinoma (HCC) after prior sorafenib therapy. The FDA…
Read More...

Constellation Pharmaceuticals has appointed Jigar Raythatha as president and CEO. He will lead the company focused on harnessing its deep scientific expertise in cancer epigenetics, to…
Read More...

Optum announced that they will collaborate with Merck to explore value-based and pay-for-performance models, known as Outcomes-Based Risk Sharing Agreements (OBRSAs), and their…
Read More...

PharmaMar has signed agreement with Eczacibasi Group to commercialize the marine-derived anticancer drug Aplidin (plitidepsin) in Turkey. Aplidin is PharmaMar´s second most advanced…
Read More...

The U.S. Patent and Trademark Office has issued a Notice of Allowance in favour of Ammonett Pharma for Patent Application No: 15/271,542, entitled “DETECTING AND TREATING GROWTH HORMONE…
Read More...

Akebia Therapeutics has appointed Rita Jain, M.D. as Senior VP and CMO. She will be responsible for leading the clinical development of the Company's HIF pipeline, including the global…
Read More...

miRagen Therapeutics announced that  MRG-106 has received orphan medicinal product designation from European Commission (EC) for the treatment of cutaneous T-cell lymphoma (CTCL). CTCL…
Read More...

Sun Pharmaceutical Industries announced that USFDA has accepted BLA for tildrakizumab submitted by Merck & Co., USA. The FDA filing acceptance follows acceptance of the regulatory…
Read More...

KBI Biopharma announced that they have planned to invest $30M for expanding its biopharmaceutical manufacturing capacity at both its Durham, NC, and Boulder, CO, facilities. KBI is…
Read More...

Selexis SA and OSE Immunotherapeutics announced that they have signed a commercial license agreement that provides OSE Immunotherapeutics with access to high performance research cell…
Read More...

Pierre Fabre announced that they signed a definitive purchase agreement with Igenica Biotherapeutics to acquire several of Igenica assets. The agreement includes innovative…
Read More...

LSNE Contract Manufacturing announced that it has signed a manufacturing supply agreement with Selecta Biosciences to support the development of biologic therapies for rare and serious…
Read More...

Intellipharmaceutics International announced that its U.S. marketing partner, Par Pharmaceutical has launched the 10 and 20 mg strengths of its generic Focalin XR (dexmethylphenidate…
Read More...